Tisagenlecleucel

Scientific Name	Tisagenlecleucel
Brand Name	Kymriah
Risk	Potential risk of T-cell malignancy associated with the use of chimeric antigen receptor (CAR) T cell Immunotherapies Secondary malignancies of T-cell origin, including chimeric antigen receptor (CAR)- positive malignancies, have been reported within weeks and up to several years following treatment of hematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy. Patients should be monitored life-long for secondary malignancies.
Educational Materials for Healthcare Professionals	Download Download
Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals	Download
Safety Communication for Healthcare Professionals	Download Download
Educational Materials for Patients	Download Download Download Download

Share page